Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/29145Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | VAN WIJMEERSCH, Bart | - |
| dc.contributor.author | Patti, F. | - |
| dc.contributor.author | Hobart, J. | - |
| dc.contributor.author | Kizlaitiene, R. | - |
| dc.contributor.author | Vanderdonckt, P. | - |
| dc.contributor.author | Shor, S. | - |
| dc.contributor.author | Andreasen, A. K. | - |
| dc.contributor.author | Uitdehaag, B. M. | - |
| dc.date.accessioned | 2019-09-10T13:58:38Z | - |
| dc.date.available | 2019-09-10T13:58:38Z | - |
| dc.date.issued | 2019 | - |
| dc.identifier.citation | EUROPEAN JOURNAL OF NEUROLOGY, 26, p. 866-866 | - |
| dc.identifier.issn | 1351-5101 | - |
| dc.identifier.uri | http://hdl.handle.net/1942/29145 | - |
| dc.description.sponsorship | Study supported by Sanofi. | - |
| dc.language.iso | en | - |
| dc.publisher | WILEY | - |
| dc.title | Baseline characteristics of patients enrolled in LEMQoL, a study assessing health-related quality of life in RRMS patients treated with alemtuzumab in a real-world clinical setting | - |
| dc.type | Journal Contribution | - |
| local.bibliographicCitation.conferencedate | JUN 29-JUL 02, 2019 | - |
| local.bibliographicCitation.conferencename | 5th Congress of the European-Academy-of-Neurology (EAN) | - |
| local.bibliographicCitation.conferenceplace | Oslo, NORWAY | - |
| dc.identifier.epage | 866 | - |
| dc.identifier.spage | 866 | - |
| dc.identifier.volume | 26 | - |
| local.format.pages | 1 | - |
| local.bibliographicCitation.jcat | M | - |
| dc.description.notes | [Van Wijmeersch, B.] Hasselt Univ, BIOMED, Rehabil & MS Ctr Overpelt, Hasselt, Belgium. [Patti, F.] Univ Catania, Teaching Hosp Policlin, Multiple Sclerosis Ctr, Catania, Italy. [Hobart, J.] Plymouth Univ, Peninsula Sch Med, Plymouth, Devon, England. [Hobart, J.] Plymouth Univ, Peninsula Sch Dent, Plymouth, Devon, England. [Kizlaitiene, R.] Vilnius Univ, Hosp Santariskiu Clin, Ctr Neurol, Clin Neurol & Neurosurg,Fac Med, Vilnius, Lithuania. [Vanderdonckt, P.] AZ Groeninge, Kortrijk, Belgium. [Shor, S.; Andreasen, A. K.] Sanofi, Amsterdam, Netherlands. [Uitdehaag, B. M.] Univ Amsterdam, Med Ctr, Amsterdam, Netherlands. | - |
| local.publisher.place | HOBOKEN | - |
| local.type.refereed | Refereed | - |
| local.type.specified | Meeting Abstract | - |
| dc.identifier.isi | 000474481004025 | - |
| item.fulltext | No Fulltext | - |
| item.fullcitation | VAN WIJMEERSCH, Bart; Patti, F.; Hobart, J.; Kizlaitiene, R.; Vanderdonckt, P.; Shor, S.; Andreasen, A. K. & Uitdehaag, B. M. (2019) Baseline characteristics of patients enrolled in LEMQoL, a study assessing health-related quality of life in RRMS patients treated with alemtuzumab in a real-world clinical setting. In: EUROPEAN JOURNAL OF NEUROLOGY, 26, p. 866-866. | - |
| item.contributor | VAN WIJMEERSCH, Bart | - |
| item.contributor | Patti, F. | - |
| item.contributor | Hobart, J. | - |
| item.contributor | Kizlaitiene, R. | - |
| item.contributor | Vanderdonckt, P. | - |
| item.contributor | Shor, S. | - |
| item.contributor | Andreasen, A. K. | - |
| item.contributor | Uitdehaag, B. M. | - |
| item.accessRights | Closed Access | - |
| crisitem.journal.issn | 1351-5101 | - |
| crisitem.journal.eissn | 1468-1331 | - |
| Appears in Collections: | Research publications | |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.